These data indicate that the highest inhibitory effect correlates with the greater activation of AMPK in prostate cancer cells and prompted us to continue the study with the compound 8c, (structure in Fig. 1C) being selected for further studies. Here, PRKAA2 is linked to prostate carcinoma.